FDA declines Eli Lilly’s bowel disease drug over manufacturing issues
Pharmafile
APRIL 14, 2023
However, concerns weren’t expressed over the clinical data package, safety or label for the medicine. Mirikizumab was hoped to become a new drug treatment for ulcerative colitis (UC), a condition where abnormal reactions in the immune system cause inflammation in the inner lining of the colon. read more
Let's personalize your content